BIIB132

Phase 1Small molecule

Biogen

BIIB132 is one of 14 small molecule programs targeting Cerebellar Ataxia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebellar AtaxiaActive, not recruiting

Cerebellar AtaxiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Cerebellar Ataxia

#DrugCompanyPhaseTrials

Fampridine

Biogen

Phase 3

1 2

Rilutek

AAzurity Pharmaceuticals

Phase 2

3 3

Lithobid

SSolvay Pharmaceuticals

Phase 2

2 4

Tasigna

AAzurity Pharmaceuticals

Phase 2

1 5

Asceniv

CSL Behring

Phase 1

1 6

Ivig

Argenx

Phase 2

1 7

SLS-005

SSeelos Therapeutics, Inc.

Phase 3

1 8

Stemchymal

SSteminent Biotherapeutics Inc.

Phase 2

2 9

CAD-1883

CCadent Therapeutics

Phase 2

1 10

Ampyra

MMerz Pharmaceuticals GmbH

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cerebellar Ataxia1 trial

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Terminated· Biogen logo

Biogen·Phase 1·NCT05160558·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BIIB132. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIIB132 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIIB132. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Biogen

BIIB132

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cerebellar Ataxia1 trial

References

Drug Info

Quick Facts

Related News